Following a full submission
AWMSG advice |
||
| Status: Not recommended | ||
Ziconotide (Prialt®) is not recommended for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia. Key factor influencing the recommendation: The case for cost effectiveness of ziconotide (Prialt®) has not been proven. |
||
|
||
Medicine details |
||
| Medicine name | ziconotide (Prialt®) | |
| Formulation | 100 micrograms/ml solution for infusion | |
| Reference number | 335 | |
| Indication | Treatment of severe chronic pain |
|
| Company | Eisai Ltd | |
| BNF chapter | Central nervous system | |
| Submission type | Full | |
| Status | Not recommended | |
| Advice number | 0708 | |
| NMG meeting date | 14/05/2008 | |
| AWMSG meeting date | 13/06/2008 | |
| Ratification by Welsh Government | 17/07/2008 | |
| Date of issue | 18/07/2008 | |